Literature DB >> 19901123

Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

Nicholas J Petrelli1, Eric P Winer, Julie Brahmer, Sarita Dubey, Sonali Smith, Charles Thomas, Linda T Vahdat, Jennifer Obel, Nicholas Vogelzang, Maurie Markman, John W Sweetenham, David Pfister, Mark G Kris, Lynn M Schuchter, Raymond Sawaya, Derek Raghavan, Patricia A Ganz, Barnett Kramer.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19901123     DOI： 10.1200/JCO.2009.26.6171

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  44 in total

1.  Thioredoxin reductase 1 knockdown enhances selenazolidine cytotoxicity in human lung cancer cells via mitochondrial dysfunction.

Authors:  Robyn L Poerschke; Philip J Moos
Journal:  Biochem Pharmacol       Date:  2010-10-12       Impact factor: 5.858

2.  Value of the metastatic lymph node ratio for predicting the prognosis of non-small-cell lung cancer patients.

Authors:  Chang-Li Wang; Yue Li; Dong-Sheng Yue; Lian-Min Zhang; Zhen-Fa Zhang; Bing-Sheng Sun
Journal:  World J Surg       Date:  2012-02       Impact factor: 3.352

3.  Survey of oral chemotherapy safety and adherence practices of hospitals in Spain.

Authors:  David Conde-Estévez; Esther Salas; Joan Albanell
Journal:  Int J Clin Pharm       Date:  2013-10-16

4.  A new disease-specific machine learning approach for the prediction of cancer-causing missense variants.

Authors:  Emidio Capriotti; Russ B Altman
Journal:  Genomics       Date:  2011-07-07       Impact factor: 5.736

5.  Clinical trial design for rare cancers: why a less conventional route may be required.

Authors:  Katherine S Panageas
Journal:  Expert Rev Clin Pharmacol       Date:  2015       Impact factor: 5.045

6.  Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials.

Authors:  Federica Cuppone; Emilio Bria; Vanja Vaccaro; Fabio Puglisi; Alessandra Fabi; Isabella Sperduti; Paolo Carlini; Michele Milella; Cecilia Nisticò; Michelangelo Russillo; Paola Papaldo; Gianluigi Ferretti; Matti Aapro; Diana Giannarelli; Francesco Cognetti
Journal:  J Exp Clin Cancer Res       Date:  2011-05-12

Review 7.  The role of HER2 in cancer therapy and targeted drug delivery.

Authors:  Wanyi Tai; Rubi Mahato; Kun Cheng
Journal:  J Control Release       Date:  2010-04-10       Impact factor: 9.776

8.  Programmed death ligand-1 expression in non-small cell lung cancer.

Authors:  Vamsidhar Velcheti; Kurt A Schalper; Daniel E Carvajal; Valsamo K Anagnostou; Konstantinos N Syrigos; Mario Sznol; Roy S Herbst; Scott N Gettinger; Lieping Chen; David L Rimm
Journal:  Lab Invest       Date:  2013-11-11       Impact factor: 5.662

9.  Does the extent of lymph nodes dissection affect the prognosis of resected stage IA non-small cell lung cancer?

Authors:  F Xu; C Wang; L Qi; W Yu; Q Li
Journal:  Clin Transl Oncol       Date:  2013-04-25       Impact factor: 3.405

10.  Febrile neutropenia in French emergency departments: results of a prospective multicentre survey.

Authors:  Stéphanie André; Pierre Taboulet; Caroline Elie; Noël Milpied; Michel Nahon; Gérald Kierzek; Mariève Billemont; Franck Perruche; Sandrine Charpentier; Hélène Clément; Jean-Louis Pourriat; Yann-Erick Claessens
Journal:  Crit Care       Date:  2010-04-19       Impact factor: 9.097
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.